RTP Mobile Logo
Select Publications

Daniel Gomez, MD, MBA

Acharya MM et al. Human neural stem cell transplantation ameliorates radiation-induced cognitive dysfunction. Cancer Res 2011;71(14):4834-45. Abstract

Brown PD et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial. JAMA 2016;316(4):401-9. Abstract

Brown PD et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013;15(10):1429-37. Abstract

Czurkó A et al. Severe spatial navigation deficit in the Morris water maze after single high dose of neonatal x-ray irradiation in the rat. Proc Natl Acad Sci USA 1997;94(6):2766-71. Abstract

DeAngelis LM et al. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;39(6):789-96. Abstract

Gondi V et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 2014;32(34):3810-6. Abstract

Mulvenna P et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet 2016;388(10055):2004-14. Abstract

Patchell RA et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280(17):1485-9. Abstract

Patchell RA et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494-500. Abstract

Slotman BJ et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: Short-term health-related quality of life and patient reported symptoms: Results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2008;27(1):78-84. Abstract

Soffietti R et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 2013;31(1):65-72. Abstract

Gregory J Riely, MD, PhD

Camidge DR et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018;379(21):2027-39. Abstract

Jordan EJ et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7(6):596-609. Abstract

Kohutek ZA et al. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases. J Neurooncol 2015;125(1):149-56. Abstract

Magnuson WJ et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: A retrospective multi-institutional analysis. J Clin Oncol 2017;35(10):1070-7. Abstract

Peters S et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377(9):829-38. Abstract

Ramalingam S et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. ESMO 2019;Abstract LBA5_PR.

Reungwetwattana T et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018;[Epub ahead of print]. Abstract

Solomon BJ et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 2018;19(12):1654-67. Abstract

Soria JC et al. Osimertinib in untreated EGFR-mutated advanced non-small cell lung cancer. N Engl J Med 2018;378(2):113-25. Abstract

Manmeet Ahluwalia, MD, FACP

Ashinuma H et al. Ceritinib treatment for carcinomatous meningitis with a secondary mutation at I1171T in anaplastic lymphoma kinase. Intern Med 2018;57(21):3153-5. Abstract

Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: Combined modality therapy. Arch Neurol 1998;55(4):506-12. Abstract

Glantz MJ et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999;5(11):3394-402. Abstract

Goldberg SB et al. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. ASCO 2018;Abstract 2009.

Grossman SA et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11(3):561-9. Abstract

Hitchens RN et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5(10):1655-62. Abstract

Liao BC et al. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis. J Thorac Oncol 2015;10(12):1754-61. Abstract

Kuiper JL et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. Lung Cancer 2015;89(3):255-61. Abstract

Umemura S et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012;77(1):134-9. Abstract

Yang JC-H et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. ASCO 2016;Abstract 9002.